Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Tesamorelin and ipamorelin are peptides that signal the body’s growth hormone system in different ways. Tesamorelin is a GHRH analog with an FDA-approved HIV lipodystrophy use; ipamorelin is a non-FDA-approved ghrelin receptor agonist. Using them together is off-label and should be considered only after clinician review. [1][2][7]
What are tesamorelin and ipamorelin?
Tesamorelin and ipamorelin are injectable peptides that work upstream of growth hormone. They do not replace growth hormone. Instead, they aim to signal pituitary somatotrophs, the cells in the pituitary gland that release endogenous growth hormone. Growth hormone then helps regulate IGF-1, fat metabolism, fluid balance, and other body processes. [3][8]
Tesamorelin: a GHRH analog
Tesamorelin, also sold as EGRIFTA SV, is a growth hormone–releasing hormone analog. It is FDA-approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. The FDA label does not approve it for general weight loss, aging, bodybuilding, sleep, or routine belly-fat reduction outside that condition. [1]
In clinical trials for HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue, also called VAT, compared with placebo. In the same clinical context, side effects included injection-site reactions, joint pain, swelling, muscle pain, numbness or tingling, and possible glucose changes, so benefits and risks must be reviewed together. [1][2]
Ipamorelin: a selective ghrelin mimetic
Ipamorelin is a growth hormone secretagogue and ghrelin receptor, or GHS-R, agonist. It has been studied for its ability to stimulate growth hormone release while appearing more selective than some older secretagogues in early studies. Ipamorelin is not FDA-approved in the U.S.; when used clinically, it is generally discussed as compounded ipamorelin via a licensed 503A pharmacy with a prescription, when allowed by law. [4][5][7]
Why they are combined
The reason clinicians may discuss the pair is that tesamorelin and ipamorelin act through different receptors. Tesamorelin copies a GHRH-type signal, while ipamorelin copies part of a ghrelin-type signal. The goal is to support a growth hormone pulse, but the tesamorelin-plus-ipamorelin combination itself has limited direct clinical trial data and is off-label. [3][4][5]
What do tesamorelin and ipamorelin do in the body?
Tesamorelin plus ipamorelin is discussed because both peptides can affect the growth hormone pathway within hours to days of use, but body-composition changes take longer and are not guaranteed. The same pathway can also raise IGF-1 and may affect glucose, swelling, joint symptoms, and carpal-tunnel-like symptoms, so monitoring matters. [1][3][8]
Growth hormone pulse and IGF-1
Growth hormone is normally released in pulses, especially during sleep. GHRH, ghrelin signals, sleep, nutrition, exercise, age, and sex hormones all affect those pulses. Tesamorelin and ipamorelin target parts of this signaling system rather than replacing growth hormone itself. [3][8]
IGF-1, short for insulin-like growth factor 1, often rises when growth hormone signaling rises. IGF-1 can be useful as a safety marker, but high IGF-1 may be a reason to pause or stop therapy depending on the clinical situation. The tesamorelin label recommends IGF-1 monitoring and warns about glucose intolerance and cancer-related concerns. [1]
Effect on visceral, or belly, fat
Tesamorelin has evidence for reducing visceral adipose tissue in adults with HIV-associated lipodystrophy. Visceral fat is the deeper fat around organs, not the same as pinchable fat under the skin. Side effects and contraindications still apply, and the FDA-approved use is narrow. [1][2]
Effect on lean muscle, sleep, and recovery
Some people ask about sleep, training recovery, and lean mass because growth hormone is linked to tissue repair and body composition. These uses are not FDA-approved for tesamorelin or ipamorelin, and direct evidence for the combination is limited. Any possible benefit should be weighed against side effects, glucose risk, and the lack of combination-specific outcome trials. [1][4][8]
Is it better to take tesamorelin and ipamorelin together?
Taking tesamorelin and ipamorelin together may have a dual-pathway rationale, but “better” is not proven for most patients. There are clinical trials for tesamorelin alone in HIV-associated lipodystrophy, while high-quality trials of the exact combination for fat loss, aging, or recovery are limited. Safety checks are still needed. [1][2][4]
Dual-pathway rationale: GHRH plus GHS-R
The theory is simple: a GHRH analog can tell pituitary somatotrophs to release growth hormone, while a ghrelin receptor agonist may amplify a growth hormone pulse. This does not mean the combo is right for everyone. The same signaling can increase IGF-1, fluid retention, nerve symptoms, and glucose concerns in some people. [1][3][4]
When a single peptide may be enough
A clinician may prefer one peptide, no peptide, or another treatment based on the goal, medical history, lab results, and FDA status. For example, tesamorelin has a specific FDA-approved indication, while ipamorelin does not. People with diabetes risk, cancer history, pregnancy, breastfeeding, or eye disease may need a different plan or no peptide therapy. [1][8]
Will tesamorelin get rid of belly fat?
Tesamorelin may reduce visceral abdominal fat in its FDA-approved population, but it does not “get rid of” belly fat for everyone and is not approved for general weight loss. In trials, benefits were measured against side effects such as injection reactions, swelling, joint pain, glucose changes, and increased IGF-1. [1][2]
What the clinical evidence shows
In randomized studies of adults with HIV-associated abdominal fat accumulation, tesamorelin lowered visceral adipose tissue compared with placebo. The FDA label also states that tesamorelin has not been shown to improve compliance with antiretroviral therapy and is not indicated for weight loss management. [1][2]
Realistic expectations versus total weight loss
Visceral fat loss is not the same as large scale weight loss. A person could have a smaller waist or less VAT without a dramatic change on the scale. For total weight-loss treatment, FDA-approved GLP-1 receptor agonists such as semaglutide and tirzepatide use a different pathway and have separate labels, risks, and contraindications. [9][10]
How long does tesamorelin plus ipamorelin take to work?
Tesamorelin plus ipamorelin timelines are not guaranteed, and combination-specific timelines are not well proven. Some people report sleep or recovery changes early, but measurable body-composition changes usually require weeks to months in studies of growth hormone pathway therapies. Side effects can also appear early, so follow-up matters. [1][2][8]
- Weeks 1-2: A clinician may ask about sleep, injection-site reactions, swelling, numbness or tingling, joint pain, headaches, and glucose symptoms. These early changes do not prove fat loss. [1]
- Weeks 3-6: Some people track waist size, training recovery, appetite changes, and side effects. Changes can be subtle, and individual results vary. [1][2]
- Weeks 6-12 and beyond: Body-composition changes, if they occur, are usually assessed over a longer window with labs and clinical review. IGF-1 or glucose concerns may change the plan. [1][8]
How is the combo used? Dosing, timing, and injection basics
Tesamorelin and ipamorelin dosing must come from the prescribing clinician. This article does not provide individualized dosing instructions. For FDA-approved tesamorelin, the product label gives the approved regimen for HIV-associated lipodystrophy; off-label combination plans should not be copied from online charts or social media. [1]
| Topic | What patients commonly ask | Educational answer | Safety note |
|---|---|---|---|
| Dose | What dose is used? | The FDA label gives a specific tesamorelin regimen for its approved HIV lipodystrophy use. Compounded or combination plans are individualized by the prescriber. | Do not change dose without clinician review; higher exposure can raise side-effect risk. [1] |
| Timing | Why is bedtime often discussed? | Growth hormone is naturally pulse-based and often linked with sleep, so clinicians may consider timing in relation to that rhythm. | Timing can depend on glucose risk, meals, sleep schedule, and other medications. [3][8] |
| Injection route | Where is it injected? | Tesamorelin is labeled for subcutaneous injection, meaning into the fatty layer under the skin. | Injection technique, site rotation, and supplies should be taught by the care team. [1] |
| Storage | Does it need special handling? | Peptide products may have specific storage and mixing rules based on the product and pharmacy. | Follow the label from the dispensing pharmacy or manufacturer; do not use cloudy, expired, or mishandled medication unless the pharmacist says it is safe. [1] |
| Monitoring | What labs are checked? | Clinicians may review IGF-1, glucose measures, pregnancy status when relevant, and other labs based on history. | Abnormal labs, high IGF-1, or side effects may lead to stopping or changing therapy. [1][8] |
Who is, and is not, a candidate?
Peptide candidacy depends on the goal, FDA indication, medical history, labs, and medications. A good evaluation should cover belly-fat pattern, HIV status when relevant, diabetes risk, cancer history, eye disease, pregnancy or breastfeeding, sleep, training, nutrition, and other prescriptions. [1][8]
Good-fit profiles
For tesamorelin, the clearest FDA-approved candidate is an adult with excess abdominal fat due to HIV-associated lipodystrophy. Other uses, including general belly-fat reduction, anti-aging, recovery, or combining with ipamorelin, are off-label and have less direct evidence. Side effects and contraindications must be reviewed before any prescription. [1][2]
Contraindications and cautions
Tesamorelin is contraindicated in pregnancy, in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma, and in patients with active malignancy. The label also warns about glucose intolerance, fluid retention, and IGF-1 monitoring. [1]
Peptide therapy may not be appropriate during breastfeeding, with active proliferative diabetic retinopathy, uncontrolled diabetes, or concerning cancer history. These cautions are especially important because growth hormone and IGF-1 signaling can affect glucose and cell-growth pathways. A clinician must evaluate the full risk picture. [1][8]
What are tesamorelin and ipamorelin side effects?
Tesamorelin and ipamorelin side effects can include local injection reactions and body-wide symptoms within days to weeks. Tesamorelin labeling reports injection-site redness or itching, joint pain, pain in extremities, swelling, muscle aches, tingling or numbness, rash, and possible glucose effects. [1]
- Injection-site reactions: redness, itching, pain, bruising, or irritation may occur with subcutaneous injections. [1]
- Fluid-related symptoms: swelling, joint pain, muscle aches, or carpal-tunnel-like tingling can happen when growth hormone signaling rises. [1][8]
- Glucose changes: tesamorelin can increase glucose intolerance risk, so people with diabetes or prediabetes need careful review. [1]
- IGF-1 elevation: IGF-1 can rise; persistently high levels may change the risk-benefit decision. [1]
- Cancer-related concern: tesamorelin is contraindicated in active malignancy, and any history of cancer needs clinician review. [1]
- Ipamorelin uncertainty: because ipamorelin is not FDA-approved, long-term safety data for common compounded use are more limited than for FDA-approved products. [4][5][7]
How does tesamorelin plus ipamorelin compare with other GH peptide options?
Tesamorelin plus ipamorelin is one of several growth-hormone-pathway options, but each has a different FDA status, evidence level, and safety profile. The most important first step is matching the treatment to the medical goal, not choosing the longest peptide stack. [1][7][8]
| Option | FDA status | Main pathway | Evidence snapshot | Key cautions |
|---|---|---|---|---|
| Tesamorelin, EGRIFTA SV | FDA-approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. [1] | GHRH analog that stimulates pituitary growth hormone release. | Randomized trials show reduced visceral adipose tissue in the approved population. [2] | Contraindications include pregnancy and active malignancy; monitor glucose and IGF-1. [1] |
| Ipamorelin | Not FDA-approved; discussed only as compounded ipamorelin via a licensed 503A pharmacy when prescribed and legally available. [7] | Ghrelin receptor, or GHS-R, agonist growth hormone secretagogue. | Early studies show growth hormone stimulation, but common wellness uses lack large outcome trials. [4][5] | Limited long-term data; potential overlap with GH-related effects such as swelling, glucose changes, and IGF-1 elevation. [1][8] |
| CJC-1295 plus ipamorelin | CJC-1295 and ipamorelin are not FDA-approved; compounded use depends on law, prescriber judgment, and pharmacy policy. [7] | GHRH analog plus GHS-R agonist concept, similar dual-pathway logic. | Often discussed in clinical and research practice, but not FDA-approved for fat loss, aging, or recovery. | Combination-specific safety data are limited; monitor for GH-pathway side effects. |
| Sermorelin | Not FDA-approved as a currently marketed drug product for common wellness uses; compounded use depends on law and prescription review. [7] | GHRH analog. | Studied historically for growth hormone diagnostic or deficiency-related contexts, not as a general anti-aging treatment. | May raise GH and IGF-1; safety review is needed in diabetes risk, cancer history, and pregnancy. |
| GLP-1 receptor agonists such as semaglutide or tirzepatide | Some brand products are FDA-approved for chronic weight management in specific patients; compounded GLP-1s are regulated differently and require a prescription. [9][10] | Incretin pathway affecting appetite, glucose, and gastric emptying. | Large trials show weight-loss effects for approved GLP-1 and GIP/GLP-1 medications in indicated patients. [9][10] | Can cause nausea, vomiting, diarrhea, gallbladder issues, and have contraindications such as certain thyroid cancer histories on labels. [9][10] |
What peptides stack well with tesamorelin and ipamorelin?
Peptide stacks are commonly combined in clinical and research practice, but that does not mean they are proven protocols. Combination-specific trials are limited, and stacking can make side effects harder to trace. Any stack should be reviewed by a clinician and a pharmacist, especially when peptides are compounded. [7][8]
- Tesamorelin plus ipamorelin: This pairing is based on GHRH plus GHS-R signaling. The safety caveat is overlapping growth-hormone-pathway effects, including IGF-1 elevation, swelling, joint pain, and glucose changes. [1][3][4]
- CJC-1295 plus ipamorelin: This is another GHRH-analog plus secretagogue pairing used in research and compounding discussions. The safety caveat is that neither is FDA-approved for fat loss, recovery, sleep, or aging, and combination-specific clinical outcome data are limited. [7]
- Sermorelin plus ipamorelin: This pairing also targets two parts of the growth hormone pulse pathway. The safety caveat is similar: possible GH-related side effects, uncertain long-term data for wellness use, and need for lab monitoring. [7][8]
How do you get tesamorelin and ipamorelin through a licensed provider?
Getting tesamorelin or ipamorelin starts with a clinical evaluation, not a shopping cart. A licensed clinician should confirm the goal, FDA status, medical history, labs, contraindications, and whether a prescription is appropriate. For most people, this review is the safest way to avoid using the wrong peptide for the wrong reason. [1][7][8]
What a clinical evaluation covers
A careful evaluation may include weight history, waist changes, HIV-associated lipodystrophy history when relevant, diabetes risk, cancer history, eye disease, pregnancy or breastfeeding status, sleep, exercise, current medications, and baseline labs. The clinician may also discuss whether a GLP-1, nutrition plan, resistance training, or no medication is a better fit. [1][8][9][10]
Compounded peptides via 503A pharmacies
A 503A compounding pharmacy prepares medication for an individual patient based on a valid prescription, under federal and state rules. Compounded tesamorelin or compounded ipamorelin is not the same as an FDA-approved product, and compounded products are not reviewed by FDA for safety, effectiveness, or quality before dispensing. [6][7]
Cost expectations
Cost can vary by peptide, pharmacy, concentration, supplies, clinician visits, lab monitoring, and whether the medication is brand or compounded. Insurance coverage is most likely when a drug is used for an FDA-approved indication and plan criteria are met; off-label peptide use is often paid out of pocket. [1][6]
Licensed telehealth providers, including Chia, can review eligibility for compounded peptide options when appropriate and coordinate prescriptions through licensed pharmacy partners. This should still include a real medical review, clear pricing, safety counseling, and a plan for follow-up.
3-min quiz
Considering peptide therapy?
A clinician can help you understand whether tesamorelin, ipamorelin, a GLP-1 option, or no medication is the right next step based on your goals and health history.
Frequently asked questions about tesamorelin and ipamorelin
Tesamorelin signals the pituitary through the GHRH pathway, while ipamorelin signals through the ghrelin receptor pathway. Both can increase growth hormone signaling, which may raise IGF-1. Tesamorelin is FDA-approved only for excess abdominal fat in adults with HIV-associated lipodystrophy; ipamorelin is not FDA-approved. [1][3][4][7]
Not necessarily. The combination has a dual-pathway rationale, but there is stronger clinical evidence for tesamorelin alone in its FDA-approved population than for the combo in general wellness or fat-loss use. A clinician should weigh possible benefits against side effects, contraindications, and limited combination-specific data. [1][2][4]
Tesamorelin can reduce visceral abdominal fat in adults with HIV-associated lipodystrophy, which is its FDA-approved use. It is not approved for general weight loss or for all types of belly fat. Side effects, glucose changes, IGF-1 increases, and contraindications must be reviewed. [1][2]
There is no guaranteed timeline for the combination. Some people notice sleep or recovery changes early, but measurable body-composition changes are usually assessed over weeks to months. Side effects can occur earlier, so follow-up and lab monitoring are important. [1][2][8]
Tesamorelin is a GHRH analog and has an FDA-approved brand product, EGRIFTA SV, for HIV-associated lipodystrophy. Ipamorelin is a ghrelin receptor agonist growth hormone secretagogue and is not FDA-approved in the U.S. [1][4][7]
No. These should be used only under clinician supervision. Tesamorelin is a prescription medication, and compounded ipamorelin, when legally available, requires a valid prescription from a licensed clinician and dispensing by an appropriate pharmacy. [1][6][7]
Yes. AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still decides whether any prescription is appropriate.
Tesamorelin is contraindicated in pregnancy, active malignancy, and several pituitary-axis conditions listed in the FDA label. Peptide therapy may also be inappropriate with breastfeeding, active proliferative diabetic retinopathy, uncontrolled diabetes, or concerning cancer history. A clinician must review your case. [1][8]
3-min quiz
Talk with a clinician about your options
If you are weighing peptides, GLP-1s, or lifestyle-first care, a medical review can help match the option to your goals, labs, and safety profile.
References
- 1.U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin) prescribing information, 2024.
- 2.Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV-associated lipodystrophy: a randomized, placebo-controlled trial. Journal of Clinical Endocrinology & Metabolism, 2007.
- 3.Müller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiological Reviews, 1999.
- 4.Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
- 5.Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677 increases growth hormone secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism, 1998.
- 6.U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers, 2024.
- 7.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting materials and 503A bulk drug substances review information, 2026.
- 8.Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 2011.
- 9.U.S. Food and Drug Administration. WEGOVY (semaglutide) prescribing information, 2024.
- 10.U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) prescribing information, 2024.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
